Biogen Idec
(NQ:
BIIB
)
197.89
-1.20 (-0.60%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 12, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Biogen Idec
< Previous
1
2
3
4
5
6
7
8
9
...
39
40
Next >
Bernie Sanders: 'Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings'
July 15, 2024
Via
Benzinga
Topics
Bankruptcy
Exposures
Financial
Legal
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
July 15, 2024
Revenue is climbing at these two drug companies -- and the trend should continue.
Via
The Motley Fool
Did Eli Lilly Just Get a Leg Up on Novo Nordisk?
July 13, 2024
Eli Lilly's latest milestone sets it apart from its rival Novo Nordisk.
Via
The Motley Fool
Key Takeaways From Biogen Analyst Ratings
July 12, 2024
Via
Benzinga
Will BIOGEN INC breakout?
July 11, 2024
Technical Insights for BIOGEN INC (NASDAQ:BIIB): Is a Breakout Imminent?
Via
Chartmill
Forecasting The Future: 19 Analyst Projections For Biogen
June 26, 2024
Via
Benzinga
(BIIB) - Analyzing Biogen's Short Interest
June 07, 2024
Via
Benzinga
Deep Dive Into Biogen Stock: Analyst Perspectives (17 Ratings)
May 22, 2024
Via
Benzinga
How Is The Market Feeling About Biogen?
May 20, 2024
Via
Benzinga
3 Highly Rated Biotech Stocks for Your July Buy List
July 05, 2024
Discover three top-rated biotech stocks that are pushing forward the pharma and biotech revolution on Wall Street.
Via
InvestorPlace
Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst
July 03, 2024
The FDA has approved Eli Lilly's Kisunla (donanemab) for early symptomatic Alzheimer's disease. Kisunla, targeting amyloid plaques, shows a significant reduction in disease progression and may reduce...
Via
Benzinga
Exposures
Product Safety
Eli Lilly Snags Long-Awaited Alzheimer's Drug Approval, Rivaling Biogen, Eisai
July 02, 2024
The company is on deck to rival Biogen and Eisai's Leqembi.
Via
Investor's Business Daily
This Is Massive News for Eli Lilly Investors
June 29, 2024
A panel of advisors to the Food and Drug Administration (FDA) recently recommended Eli Lilly's Alzheimer's candidate.
Via
The Motley Fool
The 3 Best Healthcare Stocks to Buy in June 2024
June 15, 2024
Aging populations and changing lifestyles mean healthcare is a secular story that these best healthcare stocks to buy will capitalize on.
Via
InvestorPlace
4 Best Stocks to Buy and 3 Best Stocks to Sell: June 2024
June 12, 2024
Consider making moves in these securities, each of which has news that is impacting their share price either positively or negatively.
Via
InvestorPlace
Eli Lilly's Donanemab Gains Favorable FDA Advisory Verdict, Boosting Stock Potential, Says BofA Analyst
June 11, 2024
Eli Lilly's donanemab for Alzheimer's disease garners positive FDA committee verdict, prompting analyst's bullish outlook amid comparisons to Biogen's Leqembi.
Via
Benzinga
Exposures
Product Safety
Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Win
June 11, 2024
An FDA panel unanimously backed Eli Lilly's Alzheimer's drug, but shares of Lilly and its rivals fell Tuesday.
Via
Investor's Business Daily
Exposures
Product Safety
Why Is Eli Lilly Stock Trading Higher Premarket Tuesday?
June 11, 2024
Shares of Eli Lilly surged as an FDA advisory committee endorsed donanemab, an Alzheimer's treatment shown to significantly impact early-stage patients. The drug's benefits outstripped risks, setting...
Via
Benzinga
Exposures
Product Safety
Eli Lilly Rises Again, As FDA Panel Mulls Biogen-Rivaling Alzheimer's Drug
June 10, 2024
The FDA isn't bound by the committee's recommendation, but often follows it.
Via
Investor's Business Daily
Exposures
Product Safety
The 3 Most Undervalued Pharma Stocks to Buy in June 2024
June 06, 2024
These undervalued pharma stocks to buy are worth a look because even when the economy is struggling, consumers need key medicines.
Via
InvestorPlace
Topics
Economy
Exposures
Economy
Biogen Shares Surge Following Collaboration With Delta Flight Products: What You Need To Know
June 03, 2024
Biogen Inc. (NASDAQ: BIIB) shares saw a notable uptick Monday afternoon, trading higher after the company revealed a new partnership with Delta Flight Products (DFP) to enhance air travel accessibility...
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
June 03, 2024
Via
Benzinga
Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder
May 31, 2024
The European Commission has granted exceptional marketing authorization for Biogen's Qalsody (tofersen), the first EU-approved treatment targeting the genetic cause of ALS.
Via
Benzinga
Larimar Therapeutics' Friedreich's Ataxia Investigational Drug Differentiated From Biogen's Marketed Drug
May 21, 2024
Larimar Therapeutics announces FDA lift of partial clinical hold on nomlabofusp (CTI-1601) for Friedreich's Ataxia. Data from Phase 2 study shows well-tolerated treatment with significant frataxin...
Via
Benzinga
Exposures
Product Safety
Large Cap Biopharmaceuticals Performance
May 20, 2024
The biotech sector remains a laggard YTD as can be seen by the IBB.
Via
Talk Markets
Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024
May 17, 2024
With new innovation, millions of retiring baby boomers, and an increase in mergers, biotech stocks to buy have a good deal of upside ahead.
Via
InvestorPlace
Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another
May 16, 2024
Ionis Pharmaceuticals and Biogen have halted development of BIIB105 for ALS after Phase 1/2 study results showed no impact on key clinical outcomes.
Via
Benzinga
Biogen Stock Continues Its 20% Sprint On A Twist In Alzheimer's Treatment
May 15, 2024
The company is hoping to launch an under-the-skin version of its infusion, Leqembi.
Via
Investor's Business Daily
Jim Cramer Likes Micron And Its CEO, Recommends Buying This Big Bank
May 13, 2024
Jim Cramer recommends buying Micron, adding that he likes the company's CEO Sanjay Mehrotra. As for Fidelis? "Not a favorite."
Via
Benzinga
3 S&P 500 Stocks to Rival Nvidia’s 2023 Performance in the Second Half of 2024
May 11, 2024
Let’s explore three stocks that are well-positioned to rival Nvidia’s growth rates in the second half of 2024.
Via
InvestorPlace
Topics
Stocks
Exposures
US Equities
< Previous
1
2
3
4
5
6
7
8
9
...
39
40
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.